Menu Close

Program

Program

July 27th (Sat.)

Opening Address  (13:00 ~ 13:20)

Keynote Lecture  (14:20 ~ 15:05)

“Advances in PD-1 blockade cancer immunotherapy: important roles of immune metabolism”
Kenji Chamoto (Kyoto University, Japan)

Oral Sessions  (15:05 ~ 17:30)

1-1 “Studying the combinational effect of AHCC® and immune checkpoint inhibitors in murine tumor models” 
Insoo Kang (Yale University, USA) 

1-2 “AHCC® suppresses proliferation and migration of human breast cancer cells: a molecular mechanism of action” 
Tominori Kimura (Ritsumeikan University, Japan) 

1-3 “Can AHCC® decrease the number tumorspheres in patients with solid tumor? First results of an in vitro study” 
Monika Pizon (Transfusion Center Bayreuth, Germany) 

1-4 “Updates on the benefits of AHCC🄬 supplements in patients with high and low risk HPV infections” 
Judith Smith (UTHealth, USA) 

1-5 “Development of an automated microliter-scale high-throughput evaluation system for amyloid aggregation inhibitory activity and evalation of extracts from plants collected in Hokkaido” 
Kiyotake Tokuraku (Muroran Institute of Technology, Japan) 

1-6 “Gene regulation by ETAS®50 in an in vivo model of neurodegeneration: implications in a normal setting” 
Alamelu Sundaresan (Texas Southern University, USA) 

1-7 “ETAS®50 ameliorates cognitive impairment by reducing Aβ via p-Tau pathway, and improving the circadian rhythm signaling” 
Yin-Ching Chan (Providence University, Taiwan) 

1-8 “ETAS®50 feeding could protect brain function against amyloid-beta-mediated neurotoxicity in Alzheimer model mice”
Toshihiko Torigoe (Sapporo Medical University, Japan)

Poster Sessions  (18:00 ~ 19:00)

PA-1 “New structure of polysaccharide in AHCC®” 
Kenji Sato (Kyoto University, Japan) 

PA-2 “Search for novel component with ability to suppress the hepatic stellate cell activation in AHCC🄬” 
Misako Takayama (Osaka City University, Japan) 

PA-3 “AHCC🄬 has protective effects in ischemia-reperfusion injury of the rat small intestine” 
Katsuji Tokuhara (Kansai Medical University, Japan) 

PA-4 “Does AHCC🄬 Improve outcome of mice with carcinomatous peritonitis?” 
Midori Noguchi (The University of Tokyo Hospital, Japan) 

PA-5 “Increased efficacy of oral fixed -dose combination of amphotericin B and AHCC® natural adjuvant against aspergillosis” 
Javier Capilla (Rovira i Virgili University, Spain) 

PA-6 “Treatment of HPV positive patients with oral AHCC®”
Roberto Senatori (Villa del Rosario Hospital, Italy) 

PA-7 “The efficacy of connection therapy with docetaxel, AHCC🄬, fever-range whole body hyperthermia, and low-dose nivolumab in metastatic cancer patient: a case report”
Norbert Szalus (ImmunoMedica Clinic, Poland) 

PA-8 “Long term survival achieved in a patient with hepatocellular carcinoma accompanying Vp4 after multidisciplinary therapy including hepatectomy and self-administration of AHCC🄬
Yoh Asahi (Hokkaido University, Japan) 

PA-9 “AHCC🄬 intake contributes to cancer patient’s quality of life: case report”
Hajime Tanaka (Kinokuni Clinic for integrative medicine, Japan)

PB-1 “Evaluation of AHCC® clinical effect in the treatment of patients with graves’ disease”
Zaure Zhaparkhanova (Center of Neuroendocrinology, Kazakhstan) 

PB-2 “The experience of the clinical use of AHCC® in the treatment of severe forms of herpes virus infections”
Gulnara Utepbergenova (LLP Happy Family Clinic, Kazakhstan)

PB-3 “AHCC🄬 impact: how long is it necessary to be used?”
Francisco Karkow (Fátima’s Faculty, Brazil)

PB-4 “The role of AHCC🄬 in treatment response of tuberculosis patients”
Irawaty Djaharuddin (Hasanuddin University, Indonesia)

PB-5 “The influence of Oligonol® on low-grade inflammation as a predictive factor in the course of civilization disease” Marta Mieloszyk-Pawelec (Medical Center Lifestylemed, Poland)  

PB-6″Oligonol® to prevent the relapse of ulcerative colitis: Nrf2-mediated antioxidative defense mechanism”
Ki-Baik Hahm (CHA University Bundang Medical Center, Republic of Korea)

PB-7 “Oligonol® enhances apoptotic cell death in ovarian cancer cells via suppressing NF-κB activation”
Yong-Beom Kim (Seoul National University Bundang Medical Center, Republic of Korea) 

PB-8 “Oligonol® attenuates pesticide-induced ROS production in 3T3-L1 adipocytes”
Amire Alimu (Asahikawa Medical University, Japan)

PC-1 “Liver regeneration from acute liver injury is promoted by Oligonol® a standardized oligomerized-polyphenol from Litchi chinensis fruit extract”
Hideto Yuasa (Osaka City University, Japan)

PC-2 “Cholesterol metabolism is modulated by short-term feeding of Oligonol®, a highly bioavailable source, in rats”
Kyoichi Osada (Meiji University, Japan) 

PC-3 “Effect of Oligonol® intake on menstrual distress in young women”
Masaki Taga (Seitoku University, Japan)

PC-4 “ETAS®50 attenuates UV-B irradiation-induced IL-6 expression by suppressing Akt phosphorylation in normal human dermal fibroblasts”
Ken Shirato (Kyorin University, Japan)

PC-5 “The effect of ETAS®50 single injection on stress-regulation”
Kanako Takahashi (University of Tsukuba, Japan) 

PC-6 “The clinical study about effect of ETAS®50 (a standardized extract of Asparagus officinalis stem) on dementia”
Takayuki Zenimoto (Japan Health Care College, Japan) 

PC-7 “Growth inhibition of Candida albicans by AU-1705 and its suppression of cytotoxic activity of Candida cells to adenocarcinoma cell lines DLD-1″
Kazumi Hayama (Teikyo University, Japan)

PC-8 “Anti-inflammatory effect of AU-1803 on cholic acid induced-large intestine damage in mice”
Tomoko Koda (Tokyo Healthcare University, Japan)

PD-1 “Sulforaphane has a liver-protective effect through the suppression of inducible nitric oxide synthase”
Yuki Hashimoto (Kansai Medical University, Japan)

PD-2 “Essential amino acid tryptophan inhibits induction of inducible nitric oxide synthase gene expression in interleukin-1β stimulated hepatocytes”
Masahiko Hatta (Kansai Medical University, Japan) 

PD-3 “Omeprazole inhibits the expression of inducible nitric oxide synthase in rat primary cultured hepatocytes”
Masaya Kotsuka (Kansai medical University, Japan)

PD-4 “Killing efficacy of rapid and synchronized dormancy-broken Kyoho grape seed endosperm against human breast and liver cancers”
Toshihiro Ona (Kyushu University, Japan) 

PD-5 “Plasmologen species protect HepG2 cells from lead-induced cytotoxicity and lipid oxidation”
Yue Wu (Hokkaido University, Japan) 

PD-6 “Effects of jujube on nitric oxide production in interleukin-1β-treated rat hepatocytes”
Tetsuya Okuyama (Ritsumeikan University, Japan) 

PD-7 “Studies on anti-obesity compound in Okinawan traditional vegetable “Choumeisou” and its functional enhancement by nanoparticulation”
Abu Yousuf Hossin (University of the Ryukyus, Japan) 

PD-8 “Verification of mineral improvement effect and blood date improvement effect of mineral supplement made by pressure enzyme decomposition of oyster body”
Masako Tosaka (Holisticure Medical Clinic, Japan)

Perspective New Technologies developed in Hokkaido – Poster Sessions (18:00 ~ 19:00)

HS-1 ”Usefulness of self-sampling HPV test”
Toru Sakamoto (GeneticLab Co., Ltd.)

HS-2 ”An approach for assessing mild irritants with the Bovine Corneal Opacity and Permeability test”
Yuji Higashibata (Safety Research Institute for Chemical Compounds Co., Ltd.)

HS-3 ”Changes in content of functional elements in onion extract by heat-treatment”
Ayumu Kuramoto (Tokai Bussan Co., Ltd.)

HS-4 ”Community health information network based on food function and health information”
Naohito Ito (Hokkaido Information University)

HS-5 ”Analysis of lipids from a single lipid droplet in living cells by in-tip solvent microextraction mass spectrometry”
Shu-Ping Hui (Hokkaido University)

HS-6 ”Research and development of food equipment for Hokkaido”
Yuichi Ohira (Muroran Institute of Technology)

HS-7 ”Utilization of natural zeolite mined in Hokkaido”
Ayaka Sawada (Muroran Institute of Technology)

HS-8 ”Snow bank true slime molds in Hokkaido”
Yuka Yajima (Muroran Institute of Technology)

HS-9 ”Development of functional materials using natural materials found in Hokkaido and Japan”
Koji Wakame (Hokkaido University of Science)

July 22th (Sun)

Oral Sessions  (9:00 ~ 12:00)

2-1 “The positive effect of royal jelly on mental health in a randomized controlled trial, and elucidation of its possible mechanism of action” 
Kenji Ichihara (Api Co., Ltd., Japan) 

2-2 “Constituents in Perilla extract inhibit production of nitric oxide in rat hepatocytes” 
Yukinobu Ikeya (Daiichi Univeristy of Pharmacy, Japan) 

2-3 “Study on supercooling-promoting (anti-ice nucleation) capability of Oligonol®” 
Keita Arakawa (Hokkaido University, Japan) 

2-4 “Oligonol® alleviates sarcopenia via regulation of protein turnover and mitochondrial quality in skeletal muscle” 
Sue-Joan Chang (National Cheng Kung University, Taiwan) 

2-5 “Oligonol® ameliorates hepatic fibrosis through the inhibition of FAK-YAP pathway in hepatic stellate cells” 
Hayato Urushima (Osaka City University, Japan) 

2-6 “The effect of Oligonol® in non-alcoholic fatty liver disease (NAFLD) patients” 
Anuchit Chutaputthi (Vichaiyut Hospital, Thailand) 

2-7 “AHCC🄬 activates NF-E2 p45-related factor-2 transcription and inhibits intestinal tumor development” 
Michihiro Mutoh (National Cancer Center, Japan) 

2-8 “Enhancing α-glucan rich nutritional supplement efficacy: clinical experience using AHCC®” 
Carlos Viana (Viana Healing Center N.V., Aruba) 

2-9 “The AHCC🄬 effect on clinical outcome of pulmonary tuberculosis in HIV-infected patients” 
Jamaluddin Madolangan (Hasanuddin University, Indonesia) 

Public Symposium  (13:00 ~ 15:00)

Closing Address  (15:00)

ICNIM Organizing Committee
363-32 Shin-ei, Kiyota,
Sapporo 004-0839, JAPAN
Amino Up Co.,Ltd.
TEL: +81-11-889-2233
FAX: +81-11-889-2375